132 related articles for article (PubMed ID: 12767361)
21. Pathological features of hereditary prostate cancer.
Bastacky SI; Wojno KJ; Walsh PC; Carmichael MJ; Epstein JI
J Urol; 1995 Mar; 153(3 Pt 2):987-92. PubMed ID: 7853589
[TBL] [Abstract][Full Text] [Related]
22. Clinical and pathologic outcome after radical prostatectomy for prostate cancer patients with a preoperative Gleason sum of 8 to 10.
Bastian PJ; Gonzalgo ML; Aronson WJ; Terris MK; Kane CJ; Amling CL; Presti JC; Mangold LA; Humphreys E; Epstein JI; Partin AW; Freedland SJ
Cancer; 2006 Sep; 107(6):1265-72. PubMed ID: 16900523
[TBL] [Abstract][Full Text] [Related]
23. [Is the prostate cancer screening behaviour of men with familial predisposition predictable?].
Paiss T; Kahn D; Küfer R; Maier C; Vogel W; Gschwend JE; Hautmann RE; Herkommer K
Urologe A; 2005 Apr; 44(4):387-92. PubMed ID: 15726312
[TBL] [Abstract][Full Text] [Related]
24. Impact of Postoperative Radiotherapy in Men with Persistently Elevated Prostate-specific Antigen After Radical Prostatectomy for Prostate Cancer: A Long-term Survival Analysis.
Gandaglia G; Boorjian SA; Parker WP; Zaffuto E; Fossati N; Bandini M; Dell'Oglio P; Suardi N; Montorsi F; Karnes RJ; Briganti A
Eur Urol; 2017 Dec; 72(6):910-917. PubMed ID: 28622831
[TBL] [Abstract][Full Text] [Related]
25. Radical prostatectomy for clinically advanced (cT3) prostate cancer since the advent of prostate-specific antigen testing: 15-year outcome.
Ward JF; Slezak JM; Blute ML; Bergstralh EJ; Zincke H
BJU Int; 2005 Apr; 95(6):751-6. PubMed ID: 15794776
[TBL] [Abstract][Full Text] [Related]
26. PSA doubling time as a predictor of clinical progression after biochemical failure following radical prostatectomy for prostate cancer.
Roberts SG; Blute ML; Bergstralh EJ; Slezak JM; Zincke H
Mayo Clin Proc; 2001 Jun; 76(6):576-81. PubMed ID: 11393495
[TBL] [Abstract][Full Text] [Related]
27. Relationship between systematic biopsies and histological features of 222 radical prostatectomy specimens: lack of prediction of tumor significance for men with nonpalpable prostate cancer.
Noguchi M; Stamey TA; McNeal JE; Yemoto CM
J Urol; 2001 Jul; 166(1):104-9; discussion 109-10. PubMed ID: 11435833
[TBL] [Abstract][Full Text] [Related]
28. Pathological and biochemical outcomes after radical prostatectomy in men with low-risk prostate cancer meeting the Prostate Cancer International: Active Surveillance criteria.
Mitsuzuka K; Narita S; Koie T; Kaiho Y; Tsuchiya N; Yoneyama T; Kakoi N; Kawamura S; Tochigi T; Habuchi T; Ohyama C; Arai Y
BJU Int; 2013 May; 111(6):914-20. PubMed ID: 23320782
[TBL] [Abstract][Full Text] [Related]
29. Should we replace the Gleason score with the amount of high-grade prostate cancer?
Vis AN; Roemeling S; Kranse R; Schröder FH; van der Kwast TH
Eur Urol; 2007 Apr; 51(4):931-9. PubMed ID: 16935413
[TBL] [Abstract][Full Text] [Related]
30. Preoperative parameters for predicting early prostate cancer recurrence after radical prostatectomy.
Nelson CP; Rubin MA; Strawderman M; Montie JE; Sanda MG
Urology; 2002 May; 59(5):740-5; discussion 745-6. PubMed ID: 11992850
[TBL] [Abstract][Full Text] [Related]
31. Association of vitamin D receptor FokI polymorphism with prostate cancer risk, clinicopathological features and recurrence of prostate specific antigen after radical prostatectomy.
Huang SP; Huang CY; Wu WJ; Pu YS; Chen J; Chen YY; Yu CC; Wu TT; Wang JS; Lee YH; Huang JK; Huang CH; Wu MT
Int J Cancer; 2006 Oct; 119(8):1902-7. PubMed ID: 16708371
[TBL] [Abstract][Full Text] [Related]
32. Targeted screening for prostate cancer in high risk families: early onset is a significant risk factor for disease in first degree relatives.
Valeri A; Cormier L; Moineau MP; Cancel-Tassin G; Azzouzi R; Doucet L; Baschet F; Cussenot I; L'Her J; Berthon P; Mangin P; Cussenot O; Morin JF; Fournier G
J Urol; 2002 Aug; 168(2):483-7. PubMed ID: 12131293
[TBL] [Abstract][Full Text] [Related]
33. Pretreatment prostate specific antigen doubling times: use in patients before radical prostatectomy.
Goluboff ET; Heitjan DF; DeVries GM; Katz AE; Benson MC; Olsson CA
J Urol; 1997 Nov; 158(5):1876-8; discussion 1878-9. PubMed ID: 9334621
[TBL] [Abstract][Full Text] [Related]
34. Lack of association of prostate carcinoma nuclear grading with prostate specific antigen recurrence after radical prostatectomy.
Zhou M; Hayasaka S; Taylor JM; Shah R; Proverbs-Singh T; Manley S; Rubin MA
J Urol; 2001 Dec; 166(6):2193-7. PubMed ID: 11696734
[TBL] [Abstract][Full Text] [Related]
35. Effect of family history on outcome in German patients treated with radical prostatectomy for clinically localised prostate cancer.
Heck MM; Kron M; Gschwend JE; Herkommer K
Eur J Cancer; 2012 Jun; 48(9):1312-7. PubMed ID: 22056636
[TBL] [Abstract][Full Text] [Related]
36. Prognostic significance of prostate cancer susceptibility variants on prostate-specific antigen recurrence after radical prostatectomy.
Huang SP; Huang LC; Ting WC; Chen LM; Chang TY; Lu TL; Lan YH; Liu CC; Yang WH; Lee HZ; Hsieh CJ; Bao BY
Cancer Epidemiol Biomarkers Prev; 2009 Nov; 18(11):3068-74. PubMed ID: 19900942
[TBL] [Abstract][Full Text] [Related]
37. Prostate-specific antigen persistence after radical prostatectomy as a predictive factor of clinical relapse-free survival and overall survival: 10-year data of the ARO 96-02 trial.
Wiegel T; Bartkowiak D; Bottke D; Thamm R; Hinke A; Stöckle M; Rübe C; Semjonow A; Wirth M; Störkel S; Golz R; Engenhart-Cabillic R; Hofmann R; Feldmann HJ; Kälble T; Siegmann A; Hinkelbein W; Steiner U; Miller K
Int J Radiat Oncol Biol Phys; 2015 Feb; 91(2):288-94. PubMed ID: 25445556
[TBL] [Abstract][Full Text] [Related]
38. Role of Genetic Polymorphisms in the Development and Prognosis of Sporadic and Familial Prostate Cancer.
Reis ST; Viana NI; Leite KR; Diogenes E; Antunes AA; Iscaife A; Nesrallah AJ; Passerotti CC; Srougi V; Pontes-Junior J; Salles ME; Nahas WC; Srougi M
PLoS One; 2016; 11(12):e0166380. PubMed ID: 27906997
[TBL] [Abstract][Full Text] [Related]
39. Comparison of clinically nonpalpable prostate-specific antigen-detected (cT1c) versus palpable (cT2) prostate cancers in patients undergoing radical retropubic prostatectomy.
Ghavamian R; Blute ML; Bergstralh EJ; Slezak J; Zincke H
Urology; 1999 Jul; 54(1):105-10. PubMed ID: 10414735
[TBL] [Abstract][Full Text] [Related]
40. Deoxyribonucleic acid ploidy and serum prostate specific antigen predict outcome following salvage prostatectomy for radiation refractory prostate cancer.
Amling CL; Lerner SE; Martin SK; Slezak JM; Blute ML; Zincke H
J Urol; 1999 Mar; 161(3):857-62; discussion 862-3. PubMed ID: 10022701
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
